ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2109

Are Immunosuppressants a Risk Factor Associated with Mycobacterium Tuberculosis Infection in Colombian Patients with Systemic Lupus Erythematosus? A Case-control Study

Jaime Coral-Enriquez 1, Mauricio Restrepo 2, Gloria Vasquez 3, Carlos H Muñoz-Vahos 4, Daniel Jaramillo 5, Adriana Vanegas-García 4, Ruth Eraso 6, Johanna Hernández 7, Fabian Jaimes 8 and Luis Gonzalez2, 1Grupo de Reumatología, Universidad de Antioquia, Medellin, Colombia, 2Grupo de Reumatología, Division of Rheumatology, Department of Internal Medicine, School of Medicine Universidad de Antioquia, Medellín, Colombia, 3University of Antioquia, Medellin, Antioquia, Colombia, 4Grupo de Reumatología, Universidad de Antioquia, Medellín, Antioquia, Colombia, 5Rheumatology unit, Hospital Universitario San Vicente Fundación, Medellin, Colombia, 6Grupo de Reumatología, Universidad de Antioquia; Pediatric rheumatology unit, Hospital Pablo Tobón Uribe, Medellin, Colombia, 7Division of Rheumatology, Pediatric Department, School of Medicine, Universidad de Antioquia, Medellín, Colombia, 8Department of Epidemiology, Hospital Universitario San Vicente Fundación, Universidad de Antioquia, Medellín, Colombia, Medellín, Colombia

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Infection, Systemic lupus erythematosus (SLE), tuberculosis and immunosuppressants

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Infection-Related Rheumatic Disease Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Tuberculosis (TB) infection is an important cause of morbidity and mortality in systemic lupus erythematosus (SLE) patients, especially in developing countries. Previous studies have shown that higher cumulative doses of glucocorticoids within the last year are a risk factor for Mycobacterium tuberculosis infection. However, the role of conventional immunosuppressants in TB development is controversial. The aim of this study was to identify the factors associated with TB infection in SLE patients.

Methods: A retrospective case-control study. From January 2007 to December 2017, a total of 268 patients who met the 1997 ACR revised classification criteria for SLE were included.  Cases were SLE patients diagnosed with TB by clinical, radiological, microbiological, molecular and/or histopathological criteria (SLE-TB). TB infection was classified as pulmonary, extrapulmonary or disseminated. Controls were SLE patients without TB infection (SLE-non-TB). In total 67 cases and 201 controls were assessed. The quantitative variables are expressed as means or medians with their respective measure of dispersion and the qualitative variables as absolute number and percentage. Univariable and multivariable logistic regression analyses were performed.

Results: Females were more frequent in cases (83.5%) and controls (86%). The mean age was 34 years (range 13-84 years) for cases and 36 years (range 10-87 years) for controls. No significant differences in the frequency of comorbidities [diabetes, cirrhosis and Charlson comorbidity index (CCI)], disease duration and disease activity (SLEDAI) between cases and controls were found. Pulmonary TB occurred in 46.3%, extrapulmonary TB in 16.4% and disseminated TB in 37.3% of cases. Miliary pattern on chest X-ray was found in 23.8% of cases. In the univariable analyses, kidney transplantation, cumulative glucocorticoid dose ( >2 grams) and ≥2 immunosuppressants received within the last year were associated with TB infection (11.9% in cases vs. 4.4% in controls; p= 0.04; 3.7 grams in cases vs. 2.1 grams in controls, p = 0.02; 22.7% in cases and 8.9% in controls, p= 0.02, respectively) (figure 1). By multivariable analysis, after adjusting for age, gender, disease duration, nephritis, antimalarials, immunosuppressants and CCI, cumulative glucocorticoid dose (OR 1.00; 95% CI 1.00-1.01; p=0.02) and kidney transplantation (OR 4.1; 95% CI 1.06-16.1; p=0.04) were significantly associated with TB infection occurrence. The most commonly immunosuppressants used were mycophenolate mofetil (MMF), azathioprine and cyclophosphamide, with a higher prevalence of MMF and rituximab in SLE-TB compared with SLE-non-TB patients (35.8% vs. 22.9% and 9% vs. 3%, respectively) (Figure 2).

Conclusion: Besides cumulative glucocorticoid dose ( >2 grams), kidney transplantation was found to be significantly associated with an increased risk of Mycobacterium tuberculosis infection. Although, the exposure to ≥2 immunosuppressants was more than twice in cases than in controls, it was not significant in multivariable analysis. Prospective studies are needed to clarify the potential risk of immunosuppressants for TB infection development in SLE.

Figure 1. Number of immunosuppressants received within the last year in both, cases and controls, discriminated by the cumulative dose of glucocorticoids –<2 grams or ≥2 grams-.

Figure 2. Frequency of immunosuppressants used in cases and in controls. AZA: azathioprine. CYC: cyclophosphamide. MMF: mycophenolate mofetil. MTX: methotrexate. CSA: ciclosporin A. RTX: rituximab. TAC: tacrolimus. LEF: leflunomide. SIR: sirolimus. IV Ig: intravenous immunoglobulin.


Disclosure: J. Coral-Enriquez, None; M. Restrepo, None; G. Vasquez, None; C. Muñoz-Vahos, None; D. Jaramillo, None; A. Vanegas-García, None; R. Eraso, None; J. Hernández, None; F. Jaimes, None; L. Gonzalez, None.

To cite this abstract in AMA style:

Coral-Enriquez J, Restrepo M, Vasquez G, Muñoz-Vahos C, Jaramillo D, Vanegas-García A, Eraso R, Hernández J, Jaimes F, Gonzalez L. Are Immunosuppressants a Risk Factor Associated with Mycobacterium Tuberculosis Infection in Colombian Patients with Systemic Lupus Erythematosus? A Case-control Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/are-immunosuppressants-a-risk-factor-associated-with-mycobacterium-tuberculosis-infection-in-colombian-patients-with-systemic-lupus-erythematosus-a-case-control-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/are-immunosuppressants-a-risk-factor-associated-with-mycobacterium-tuberculosis-infection-in-colombian-patients-with-systemic-lupus-erythematosus-a-case-control-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology